MindWalk Holdings (HYFT) Research & Development (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Research & Development of $1146.1 for Q2 2026, up 29.43% year-over-year from $885.44 in Q2 2025, and down 99.87% quarter-over-quarter from $874771.6 in Q1 2026.
Powered by 
Analysis
MindWalk Holdings (HYFT) Research & Development (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Research & Development for 7 consecutive years, with $1146.1 the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 29.43% year-over-year to $1146.1; the TTM figure through Apr 2026 stood at $877884.4 (down 99.92% YoY), while the FY2026 annual figure was $3.6 million, up 19.07% from the prior year.
- Research & Development declined to $1146.1 in Q2 2026 per HYFT's latest filing, from $874771.6 in the prior quarter.
- Across five years, Research & Development topped out at $1.1 billion in Q3 2024 and bottomed at $883.08 in Q4 2025.
- Historically, Research & Development has averaged $134.9 million across 5 years, with a median of $720875.9 in 2024.
- Annual changes were most pronounced in 2023 — Research & Development jumped 15792617.46% — and 2025, when it tumbled 100.0%.
- MindWalk Holdings' Research & Development stood at $3.8 million in 2022, then jumped by 16251.84% to $615.8 million in 2023, then plunged by 99.88% to $736682.4 in 2024, then slumped by 99.88% to $883.08 in 2025, then climbed by 29.78% to $1146.1 in 2026.
- Business Quant data shows HYFT's Research & Development at $1146.1 in Q2 2026, $874771.6 in Q1 2026, and $883.08 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 210.03 Mn |
| 10 | MindWalk Holdings | 61.22 Mn | 52.95 Mn | 1.82 Mn | 1.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 1.15 Mn |
| Jan 31, 2026 | 874,771.62 |
| Oct 31, 2025 | 883,076.78 |
| Jul 31, 2025 | 763.45 Mn |
| Apr 30, 2025 | 885,438.15 |
| Jan 31, 2025 | 643,846.14 |
| Oct 31, 2024 | 736,682.43 |
| Jul 31, 2024 | 1.09 Bn |
| Apr 30, 2024 | 705,069.39 |
| Jan 31, 2024 | 740,461.20 |
| Oct 31, 2023 | 615.81 Mn |
| Jul 31, 2023 | 709.50 Mn |
| Apr 30, 2023 | 674,012.85 |
| Jan 31, 2023 | 1.16 Mn |
| Oct 31, 2022 | 3.77 Mn |
| Jul 31, 2022 | 4.49 Mn |
| Apr 30, 2022 | 1.48 Mn |
| Jan 31, 2022 | 1.44 Mn |
| Oct 31, 2021 | 2.27 Mn |
| Jul 31, 2021 | 910,847.02 |